These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27726115)

  • 81. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.
    Chu MP; Hecht JR; Slamon D; Wainberg ZA; Bang YJ; Hoff PM; Sobrero A; Qin S; Afenjar K; Houe V; King K; Koski S; Mulder K; Hiller JP; Scarfe A; Spratlin J; Huang YJ; Khan-Wasti S; Chua N; Sawyer MB
    JAMA Oncol; 2017 Jun; 3(6):767-773. PubMed ID: 27737436
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer.
    Thakur MK; Gadgeel SM
    Semin Respir Crit Care Med; 2016 Oct; 37(5):760-770. PubMed ID: 27732997
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
    Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
    Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    Neal JW; Dahlberg SE; Wakelee HA; Aisner SC; Bowden M; Huang Y; Carbone DP; Gerstner GJ; Lerner RE; Rubin JL; Owonikoko TK; Stella PJ; Steen PD; Khalid AA; Ramalingam SS;
    Lancet Oncol; 2016 Dec; 17(12):1661-1671. PubMed ID: 27825638
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
    Sullivan I; Planchard D
    Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies.
    Ellingson BM; Wen PY; Cloughesy TF
    Cancer J; 2021 Sep-Oct 01; 27(5):395-403. PubMed ID: 34570454
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER-Mitochondria Interface in Oncogene-Driven NSCLC.
    De Rosa V; Iommelli F; Terlizzi C; Leggiero E; Camerlingo R; Altobelli GG; Fonti R; Pastore L; Del Vecchio S
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439291
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Predicting EGFR mutation subtypes in lung adenocarcinoma using
    Liu Q; Sun D; Li N; Kim J; Feng D; Huang G; Wang L; Song S
    Transl Lung Cancer Res; 2020 Jun; 9(3):549-562. PubMed ID: 32676319
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.
    Lheureux S; Denoyelle C; Ohashi PS; De Bono JS; Mottaghy FM
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):41-54. PubMed ID: 28396911
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Early
    De Rosa V; Iommelli F; Monti M; Mainolfi CG; Fonti R; Del Vecchio S
    EJNMMI Res; 2016 Dec; 6(1):74. PubMed ID: 27726115
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
    Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
    Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
    [TBL] [Abstract][Full Text] [Related]  

  • 93. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by
    Iommelli F; De Rosa V; Terlizzi C; Monti M; Panico M; Fonti R; Del Vecchio S
    Clin Cancer Res; 2018 Jul; 24(13):3126-3136. PubMed ID: 29618618
    [No Abstract]   [Full Text] [Related]  

  • 95. Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer.
    De Rosa V; Iommelli F; Monti M; Fonti R; Votta G; Stoppelli MP; Del Vecchio S
    Clin Cancer Res; 2015 Nov; 21(22):5110-20. PubMed ID: 26216352
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.